Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced the publication of a peer-reviewed study in EP Europace evaluating vMap-guided activation mapping and ...

Catheter ablation guided by electroanatomic mapping is now a viable treatment option to reduce episodes of recurrent ventricular tachycardia (VT) in patients who have experienced myocardial infarction ...

Patients with structural heart disease are at risk for life-threatening ventricular tachycardias (VTs). Implantable cardioverter-defibrillators (ICDs) can terminate VT, but often at the cost of ...

The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation procedures guided by ...

The first randomized trial to investigate preventive ablation of a potential arrhythmogenic substrate associated with coronary chronic total occlusion (CTO) in patients at high risk of ventricular ...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermedical ®, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced today that the U.S. Food & Drug Administration (FDA) has approved an ...

Baltimore, MD - A report published this week has shown a high rate of ventricular tachycardia (VT) recurrence—as high as 75% at 14 months—in arrhythmogenic right ventricular dysplasia/cardiomyopathy ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; “Adagio Medical”, “Adagio” or the “Company”), a leading innovator in catheter ablation technologies, today announced ...

A technique borrowed from radiation oncology that takes the catheter out of catheter ablation continued to put in an impressive performance, observers say, in the longest yet follow-up of patients ...

Ventricular tachycardia (VT) is caused by abnormal electrical circuits originating from diseased areas of the ventricular myocardium. It usually results in a rapid heartbeat, preventing effective ...

BERLIN, Germany—Performing ventricular tachycardia (VT) ablation before placement of a primary prevention implantable cardioverter-defibrillator (ICD) had a clinical benefit in a selected group of ...

NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...